Tag: Hemostemix

Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors

CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and development activities.  Further to the Company’s press release dated November 8, 2018 where it discussed research and development initiatives and […]

Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial

CALGARY, Alberta, Oct. 09, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that it has received all approvals from three new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical limb ischemia (“CLI”).  In […]

Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders

CALGARY, Alberta, Sept. 27, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that at the Annual and Special Meeting of Shareholders (the “Meeting”) held on September 26, 2018, shareholders overwhelmingly approved all the resolutions placed before the Meeting and as outlined […]

Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial

CALGARY, Alberta, July 18, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has treated three additional patients including its first two patients in the United States under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”).  The first […]